# 바이오스페이스 일일 뉴스 리포트 - 2025년 12월 12일


## 주요 헤드라인

1. **AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/ac-immunes-parkinsons-immunotherapy-appears-to-slow-disease-progression>

2. **AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/ac-immunes-parkinsons-immunotherapy-appears-to-slow-disease-progression>

3. **Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/lillys-retatrutide-scores-triple-trial-triumph-with-26-weight-loss-but-new-safety-signal-emerges>

4. **Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/lillys-retatrutide-scores-triple-trial-triumph-with-26-weight-loss-but-new-safety-signal-emerges>

5. **Pfizer Builds Case for Tukysa as ‘New Standard Regimen’ in First-Line Metastatic Breast Cancer (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/pfizer-builds-case-for-tukysa-as-new-standard-regimen-in-first-line-metastatic-breast-cancer>

6. **Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/zealand-bets-up-to-2-5b-in-metabolic-pact-with-chinese-biotech>

7. **Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/roches-oral-serd-cuts-death-risk-by-30-in-early-stage-breast-cancer>


---
*2025년 12월 12일 바이오스페이스 뉴스 피드에서 생성된 리포트*